• 2017

    October 2017

    The U.S. Food and Drug Administration approves Yescarta, a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

    August 2017

    Gilead acquires Santa Monica, California-based Kite Pharma.

    July 2017

    The U.S. Food and Drug Administration approves Vosevi, the first pan-genotypic single tablet regimen for adults with chronic hepatitis C infection who failed certain direct-acting antiviral regimens.

  • 2016

    November 2016

    Vemlidy logo

    The U.S. Food and Drug Administration approves Vemlidy®, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

    June 2016

    The U.S. Food and Drug Administration approves Epclusa®, the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.

    April 2016

    The U.S. Food and Drug Administration approves Descovy®, a fixed-dose combination for HIV-1 infection.

    Gilead acquires Nimbus Apollo, Inc., a wholly-owned subsidiary of Cambridge, Massachusetts-based Nimbus Therapeutics, and its Acetyl-CoA Carboxylase (ACC) inhibitor program.

    March 2016

    The U.S. Food and Drug Administration approves Odefsey®, a complete once-daily, single tablet regimen for HIV-1 infection.

  • 2015

    November 2015

    The U.S. Food and Drug Administration approves Genvoya®, a complete once-daily, single tablet regimen for HIV-1 infection.

    May 2015

    Gilead acquires Copenhagen, Denmark-based EpiTherapeutics ApS.
  • 2014

    October 2014

    The U.S. Food and Drug Administration approves Harvoni® for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.

    September 2014

     

    The U.S. Food and Drug Administration approves Tybost® for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.

     

    The U.S. Food and Drug Administration approves Vitekta® as part of combination antiretroviral therapy in adults with HIV-1 infection.

    July 2014

    The U.S. Food and Drug Administration approves Zydelig® (idelalisib) for the treatment of certain patients with relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.

  • 2013

    December 2013

    The U.S. Food and Drug Administration approves Sovaldi® for the treatment of chronic hepatitis C (CHC) as a component of a combination antiviral treatment regimen.

    February 2013

    Gilead acquires Mississauga, Ontario-based YM BioSciences.

  • 2012

    December 2012

    Gilead’s Board of Directors approves a two-for-one stock split.

    August 2012

    The U.S. Food and Drug Administration approves Stribild®, a complete once-daily, single tablet regimen for HIV-1 infection in treatment-naïve adults.

    July 2012

    The U.S. Food and Drug Administration approves Truvada®, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

    January 2012

    Gilead acquires Princeton, New Jersey-based Pharmasset.

  • 2011

    November 2011

    European Medicines Agency approves Eviplera® for the treatment of HIV.

    August 2011

    The U.S. Food and Drug Administration approves Complera®, a complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults.

    Gilead acquires Oceanside, California-based clinical biologics manufacturing facility from Genentech.

    July 2011

    Gilead becomes the first pharmaceutical company to join the Medicines Patent Pool to accelerate access to HIV/AIDS therapies in developing countries.

    April 2011

    Gilead acquires Seattle, Washington-based Calistoga Pharmaceuticals.

    January 2011

    Gilead acquires Palo Alto, California-based Arresto Biosciences.
  • 2010

    July 2010

    Gilead acquires Branford, Connecticut-based CGI Pharmaceuticals.

    February 2010

    The U.S. Food and Drug Administration approves Cayston® for the improvement of respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.

  • 2009

    April 2009

    Gilead acquires Palo Alto, California-based CV Therapeutics.
  • 2008

    August 2008

    The U.S. Food and Drug Administration approves Viread® for chronic hepatitis B in adults.

    April 2008

    European Medicines Agency approves Viread® for the treatment of chronic hepatitis B.
  • 2007

    December 2007

    European Medicines Agency approves Atripla® for the treatment of HIV.

    November 2007

    Gilead and LG Life Sciences, Ltd. enter into an exclusive license agreement focused on the development of caspase inhibitors for the treatment of fibrotic diseases.

    October 2007

    Atripla® approved by Health Canada.

    August 2007

    Gilead acquires Cork, Ireland manufacturing facility from Nycomed.

    June 2007

    The U.S. Food and Drug Administration approves Letairis® for the treatment of pulmonary arterial hypertension.

    May 2007

    Gilead’s Board of Directors approves a two-for-one stock split.

  • 2006

    November 2006

    Gilead acquires Edmonton, Alberta-based Raylo Chemicals.

    Gilead acquires Westminster, Colorado-based Myogen.

    August 2006

    Gilead acquires Seattle, Washington-based Corus Pharma.
    Gilead announces licensing agreements with India-based companies for manufacturing and distribution of generic versions of Viread® in the developing world.

    July 2006

    The U.S. Food and Drug Administration approves Atripla®, the first once-daily single tablet regimen for adults with HIV-1 infection.

    January 2006

    The U.S. Food and Drug Administration approves Ranexa® for the treatment of chronic angina.
  • 2005

    March 2005

    Gilead expands its Access Program to include additional countries in the Caribbean and Latin America, meaning that 97 countries, representing an estimated 70 percent of the global HIV/AIDS epidemic, are now included in the company’s access effort.
    Gilead establishes non-profit Foundation, with a mission of improving access to healthcare for people around the world.

    February 2005

    European Medicines Agency approves Truvada® for the treatment of HIV.

  • 2004

    December 2004

    The U.S. Food and Drug Administration approves Macugen® for age-related macular degeneration.

    August 2004

    Truvada is added to Gilead's Access Program and U.S. Advancing Access Program.

    The U.S. Food and Drug Administration approves Truvada®, a one-tablet, once-a-day fixed-dose co-formulation of Emtriva and Viread for HIV combination therapy.

    July 2004

    Gilead's Board of Directors approves a two-for-one stock split.

    June 2004

    Gilead Sciences is added to the S&P 500®.
  • 2003

    October 2003

    European Medicines Agency approves Emtriva® for the treatment of HIV

    July 2003

    The U.S. Food and Drug Administration approves Emtriva® for the treatment of HIV.

    April 2003

    Gilead launches its Access Program to provide the anti-HIV therapy Viread® in 68 developing countries at significantly reduced prices.

    March 2003

    European Medicines Agency approves Hepsera® for the treatment of chronic hepatitis B.

    January 2003

    Gilead acquires Durham, North Carolina-based Triangle Pharmaceuticals.

  • 2002

    September 2002

    The U.S. Food and Drug Administration approves Hepsera® for the treatment of chronic hepatitis B.

    February 2002

    Gilead's Board of Directors approves a two-for-one stock split.

    European Medicines Agency approves Viread for the treatment of HIV infection.

    January 2002

    Gilead reports first year of positive cash flow from operations.


  • 2001

    October 2001

    The U.S. Food and Drug Administration approves Viread® for the treatment of HIV infection.

    February 2001

    Gilead's Board of Directors approves a two-for-one stock split.



  • 2000

    July 2000

    The U.S. Food and Drug Administration approves AmBisome® for the treatment of cryptococcal meningitis in HIV-infected patients.

  • 1999

    October 1999

    The U.S. Food and Drug Administration approves Tamiflu® for the treatment of influenza A and B in adults.

    July 1999

    Gilead acquires Boulder, Colorado-based NeXstar Pharmaceuticals and establishes international operations.

  • 1992

    January 1992

    Gilead completes its initial public offering of 5.75 million shares of Common Stock, for total proceeds of $86.25 million.

  • 1991

    November 1991

    Gilead in-licenses nucleotides from The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic and Rega Stichting. 

  • 1990

    December 1990

    AmBisome® liposome for injection receives first approval in Europe for the treatment of severe fungal infections.

  • 1987

    June 1987

    Gilead Sciences is founded.